Mixing Drugs with Plasmalyte: Compatibility Considerations
Mixing medications with Plasmalyte should be avoided unless specific compatibility has been validated by the manufacturer or accredited laboratory, as drug-fluid interactions can lead to precipitation, pH changes, and altered drug stability that may harm patients. 1
General Principles for Drug-Fluid Mixing
The fundamental issue is that drug compatibility with IV fluids is highly specific to the exact drug formulation, concentration, pH, and even the specific tubing and flow rates used. 1 The pH of Plasmalyte (approximately 7.4) differs significantly from other common IV fluids, which affects how drugs behave when mixed with it.
Key Compatibility Concerns
Adrenergic drugs (epinephrine, norepinephrine, dopamine) should never be mixed with alkaline solutions in the IV line, as they become inactivated. 2 While Plasmalyte has a near-physiologic pH of 7.4, this principle applies to any alkaline environment.
The 2018 ESPGHAN/ESPEN guidelines provide the strongest recommendation: mixing of medications with any IV solution in administration lines should be avoided unless validated by appropriate testing. 1 This is a strong recommendation with strong consensus.
Specific Drug Compatibility Data with Plasmalyte
Compatible Medications (Based on Research Evidence)
The following drugs have been validated as physically and chemically compatible with Plasmalyte 148 for up to 24 hours at clinically relevant concentrations:
- Morphine 3, 4
- Fentanyl 5, 3, 4
- Clonidine 4
- Aminophylline 4
- Salbutamol 4
- Adrenaline (epinephrine) 3
- Dobutamine 3
- Dopamine 3
- Milrinone 3
- Acyclovir 6
- Ampicillin 6
- Aztreonam 6
- Ciprofloxacin 6
- Gentamicin 6
- Heparin 6
- Hydrocortisone 6
- Levofloxacin 6
- Meropenem 6
- Piperacillin-tazobactam 6
- Tobramycin 6
- Vancomycin 6
- Potassium chloride 5
Incompatible Medications (Do Not Mix)
Midazolam is incompatible with Plasmalyte and precipitates when mixed, showing both visual and sub-visual particle formation. 5, 3, 4 This incompatibility occurs because Plasmalyte's pH (~7.4) exceeds midazolam's solubility limits.
Ketamine shows incompatibility with Plasmalyte 148 at certain mixing ratios, with particle formation confirmed. 5
Amiodarone demonstrates turbidimetric incompatibility with Plasmalyte A and should not be co-administered via Y-site. 6
Furosemide shows variable stability—compatible at lower concentrations but may be unstable at higher concentrations, particularly with Plasmalyte + 5% glucose at 24 hours. 3, 4
Ceftriaxone at 40 mg/mL is physically incompatible with Plasmalyte A beyond 8 hours. 7
Cefepime is incompatible with Plasmalyte at all tested concentrations (10,20,40 mg/mL) beyond 1 hour. 7, 6
Clinical Decision Algorithm
- First, check if the specific drug has validated compatibility data with Plasmalyte at your intended concentration and duration
- If no data exists or data shows incompatibility: Use a separate IV line or choose an alternative compatible fluid (typically 0.9% saline for most drugs)
- Never mix drugs directly in the Plasmalyte bag unless you have manufacturer validation
- For Y-site administration: Only proceed if specific Y-site compatibility has been demonstrated for your exact drug concentration and flow rate
- When in doubt: Use separate IV access or consult pharmacy for compatibility verification
Critical Pitfalls to Avoid
- Do not assume compatibility based on other fluids: A drug compatible with normal saline may not be compatible with Plasmalyte due to pH differences
- Do not extrapolate between concentrations: Compatibility at one concentration does not guarantee compatibility at another
- Watch for "non-circulating fluid spaces" in tubing where drugs can pool and precipitate, particularly at low flow rates 1
- Be aware that precipitation may not be immediately visible: Sub-visual particles can form that require turbidimetric analysis to detect 5, 3
Practical Recommendations
For critically ill patients requiring multiple infusions, use dedicated IV lines for incompatible medications rather than attempting to mix them with Plasmalyte. The risk of in-line precipitation causing emboli or drug inactivation outweighs the convenience of using fewer IV access points.
When Plasmalyte is chosen as the maintenance fluid (which has advantages over 0.9% saline in avoiding hyperchloremic acidosis 8, 9), ensure that all concurrent medications are administered through validated compatible routes or separate access.